• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org


inca header plovdiv
4th INCA NET Patient Advocacy Summit

For a fourth time since 2012 INCA brings together NET patient advocate leaders from around the globe to learn about the latest treatment developments and research, as well as share best practices and build common platforms.

4th INCA NET Patient Advocacy Summit in Plovdiv (Bulgaria), 11-13 July 2016.

Read More
ESO Masterclass in Cancer Patient Advocacy

INCA has had the pleasure of participating in the 2nd Masterclass in Cancer Patient Advocacy: Working Towards Stronger and More Effective Advocacy in Europe, taking place on 24-26 June in Milan, Italy.


INCA shares best practice

Evidence-based activism at the 2nd Masterclass in Cancer Patient Advocacy held by European School of Oncology (ESO)

Read More
inca header survey
First Global Neuroendocrine Tumor Patient Survey Results Published in Journal of Global Oncology

  “Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” - a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and Novartis, was published in the Journal of Global Oncology. The Global NET Patient Survey is the first large, global initiative that attempts to characterize…

Read More
cycling 3
Cycling for Net

Our Cycling Team will  leave Paris on 24 June, to arrive in Winchester on 28 June.  Professor Ramage will join our team, composed mainly of patients and carers, and he will accompany them to Winchester. In May 2015, members of our Association APTED (Association de Patients porteurs de Tumeurs Endocrines Diverses) met in Paris to…

Read More
UK - sign the petition web
INCA support the NET Cancer community in UK

  INCA Strongly Supports the NET Community in the UK in its efforts to access to PRRT INCA strongly supports the neuroendocrine (NET) cancer community in the United Kingdom in its efforts to alleviate the devastating side effect of removing an outstanding, life changing treatment, Peptide Receptor Radionuclide Therapy (PRRT) Lutetium-177 DOTA Octreotate, for patients with progressive, inoperable neuroendocrine…

Read More
Epidemiology-infographic Header INCA
Epidemiology for NET Cancer

Epidemiology is the study and analysis of the patterns, causes, and effects of health and disease conditions in defined populations. It is the cornerstone of public health, and shapes policy decisions and evidence-based practice by identifying risk factors for disease and targets for preventive healthcare. Infographics about NET cancers   There are several sources for our…

Read More
Teodora at esmo 900
INCA Appoints First Executive Director

PRESS RELEASE,  March 2, 2016   The International Neuroendocrine Cancer Alliance (INCA) Appoints First Executive Director, Teodora Kolarova     Ron Hollander, President of the International Neuroendocrine Cancer Alliance (INCA) and Executive Director of the NET Research Foundation (USA), is pleased to announce the appointment of Teodora Kolarova of Bulgaria as INCA’s first Executive Director. Ms. Kolarova…

Read More
INCA bro-ncd
INCA Brochure

“It is the passion to change things for the betterment of neuroendocrine cancer patients that drives us forward as a deeply committed team, to unite patient advocates from around the globe in this effort.” The INCA Team. Read our new brochure here ....                     The International…

Read More
ron1 web


Blog post by Ron Hollander.

The International Neuroendocrine Cancer Alliance (INCA) held its annual  Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide. 

INCA summit Oxford
(L-R) INCA Secretary Jo Grey (UK) – Association for Multiple Endocrine Neoplasia Disorders (AMEND); CFCF Funded Researcher Tim Meyer, MD, PhD – UCL Cancer Institute, University College London; INCA President Teodora Kolarova (Bulgaria) – APOZ & Friends; Ron Hollander – CFCF Executive Director; Josh Mailman – President of NorCal CarciNET Community; Yoshiyuki Majima (Japan) – PanCan

Read More
bill1 web
Good news for NET Cancer


Blog post by Bill Claxton.

Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.

“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).


Read More
Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button